SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Company Response from Armata Pharmaceuticals, Inc. (ARMP) (CIK 0000921114) (ARMP) — May 13, 2015

Armata Pharmaceuticals, Inc. (ARMP) (CIK 0000921114)
Date: May 13, 2015 · CIK: 0000921114 · Accession: 0001144204-15-030016

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-203454

Date
May 13, 2015
Author
/s/ David E. Bosher
Form
CORRESP
Company
Armata Pharmaceuticals, Inc. (ARMP) (CIK 0000921114)

Letter

Re: AmpliPhi Biosciences Corporation

May 13, 2015

BY EDGAR

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

Registration Statement on Form S-1, as amended

File No. 333-203454

Request for Acceleration of Effectiveness

Ladies and Gentlemen:

Pursuant to Rule 461 of the Securities Act of 1933, as amended, AmpliPhi Biosciences Corporation, a Washington corporation (the “Company”), hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement to become effective at 4:00 PM, New York City time, on May 14, 2015, or as soon thereafter as possible on such date. The Company also requests the Commission to specifically confirm such effective date and time to the Company in writing.

The Company hereby acknowledges that:

· Should the Commission or the staff of the Commission (the “Staff”), acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;

· The action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and

· The Company may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Should you have any questions or require any additional information with respect to this filing, please contact the undersigned at (804) 827-2524. Thank you for your assistance and cooperation.

Sincerely,
AMPLIPHI BIOSCIENCES CORPORATION

Show Raw Text
CORRESP
1
filename1.htm

May 13, 2015

BY EDGAR

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

    Re:
    AmpliPhi Biosciences Corporation

    Registration Statement on Form S-1, as amended

    File No. 333-203454

    Request for Acceleration of Effectiveness

Ladies and Gentlemen:

Pursuant to Rule 461 of the Securities
Act of 1933, as amended, AmpliPhi Biosciences Corporation, a Washington corporation (the “Company”), hereby
requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the
above-referenced Registration Statement to become effective at 4:00 PM, New York City time, on May 14, 2015, or as soon thereafter
as possible on such date. The Company also requests the Commission to specifically confirm such effective date and time to the
Company in writing.

The Company hereby acknowledges that:

 · Should the Commission or the staff of the Commission (the “Staff”), acting pursuant
to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect
to the filing;

 · The action of the Commission or the Staff, acting pursuant to delegated authority, in declaring
the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure
in the filing; and

 · The Company may not assert Staff comments and the declaration of effectiveness as a defense in
any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Should you have any questions or require
any additional information with respect to this filing, please contact the undersigned at (804) 827-2524. Thank you for your assistance
and cooperation.

    Sincerely,

    AMPLIPHI BIOSCIENCES CORPORATION

    /s/ David E. Bosher

    David E. Bosher

    Interim Chief Financial Officer

    AmpliPhi Biosciences Corporation

 cc: Stephen B. Thau, Esq., Morrison & Foerster LLP

US: 800 East
Leigh Street, Suite 209, Richmond, VA 23219

AU: Unit 7
27 Dale Street, Brookvale 2100 NSW